Development of novel oxazolo [5,4 d ] 
Development of novel oxazolo[5,4-d]pyrimidines as competitive CB2 neutral
antagonists [ Abbreviations: Boc, tert-butyloxycarbonyl; cAMP, cyclic adenosine monophosphate; CHO, Chinese hamster ovary cells; CHO-CB2, Chinese hamster ovary cells expressing CB2 receptors; CHO-WT, Chinese hamster ovary cells wild type; DIEA, N,N-diisopropylethylamine; ECS, endocannabinoid system; KHMDS, potassium bis(trimethylsilyl)amide; SAR, structure-activity relationship; TFA, trifluoroacetic acid.
Introduction
The endocannabinoid system (ECS), present in mammals and comprising two primary G protein-coupled receptors, is linked with endogenous lipid mediators and relevant enzymes responsible for the synthesis and degradation of lipid mediators [2] .
Due to its functions in the regulation of pain, inflammation, motor behavior, emotion, appetite and addiction, the ECS has been regarded as an ideal target with broad therapeutic potential [2] [3] [4] . The two G protein-coupled cannabinoid CB1 and CB2 receptors, are predominantly expressed in the central nervous system (e.g. brain) and immune cells (e.g. macrophages), respectively [3, [5] [6] [7] . CB1 receptor antagonists have shown potential in the treatment of addiction and obesity. It has been demonstrated that the administration of a CB1 antagonist (e.g., rimonabant) brings about a reduction of drug-seeking behaviors and weight loss [8] [9] [10] [11] . By contrast, CB2 receptor agonists lead to down regulation of inflammation and pain by restoring the equilibrium between pro-and anti-inflammatory cytokines [3, 5, 7, 12] . Moreover, several studies have shown that CB2 inverse agonists can regulate bone proliferation and relieve inflammation through modulating the migration of immune cells [13] [14] [15] . However, research on CB2 neutral antagonists is rare, and their therapeutic potential remains unknown. In some cases, CB2 neutral antagonists can be considered as ideal tools for investigating the biological function of receptors due to their ability to combine with receptors without altering corresponding biomolecular levels [16, 17] . In addition, targeting CB1 receptors rather than CB2 receptors has been demonstrated to induce tetrahydrocannabinol-like side effects (e.g., hypomotility, hypothermia, catalepsy) [18] . Thus, the development of selective CB2 ligands has been considered as an interesting therapeutic strategy.
Over the course of the last few decades, the development of CB2 ligands has significantly progressed. Numerous selective CB2 ligands have shown therapeutic potential in a wide range of in vivo models, including pain, inflammation, cancer, immune disorders, neurodegenerative diseases and bone disorders [14, [19] [20] [21] [22] [23] [24] [25] [26] .
Specifically, more than ten CB2 selective agonists have been reported to be under evaluation in clinical trials for the treatment of inflammation and pain [12] . For instance, compound 1 (GRC10693, Figure 1 ), developed by Glenmark Pharmaceuticals, successfully completed Phase I trials in 2009 [27] . It was intended to be used for pain remission, including neuropathic pain and inflammatory pain.
Moreover, Eli Lilly and Co. disclosed a series of purines as selective CB2 agonists [28] [29] [30] [31] . Of note, compound 2 (LY2828360, Figure 1) , derived from the lead compound 3 (Figure 1 ), has been recognized as a potent and efficacious analgesic agent in a rat model of osteoarthritis related chronic pain at a 1 mg/kg oral dose [30] . Accordingly, clinical trials for the treatment of osteoarthritic knee pain were performed [32] . Additionally, it was reported that compound 4 (AM630, Figure 2) , one of the most potent CB2 inverse agonist identified to date, can attenuate osteoporosis [25, 33, 34] . Two other notable CB2 inverse agonists, 5 (Sch225336, Figure 2 ) and 6 (Sch414319, Figure 2 ), have been shown to reduce inflammation through modulating the recruitment of immune cells [13, 15] . Scaffold hopping is a useful and powerful strategy for drug discovery. It has been widely used for the design of potential bioactive molecules [35] [36] [37] . In general, scaffold hopping incorporate heterocycle replacement, ring opening and closure, pseudopeptides and peptidomimetics, and topology/shape-based scaffold hopping [36] .
Herein, we applied the heterocycle replacement-based scaffold hopping strategy toward compound 3, a CB2 agonist developed by Eli Lilly and Co [30] .
Oxazolo [5,4-d] pyrimidine is a versatile scaffold used for the design of bioactive ligands against enzymes or receptors [38] [39] [40] . Hence, we replaced the purine core by this scaffold, with the intention of observing its influence on bioactivity toward CB2 receptors ( Figure 3) . Afterwards, we carried out pharmacomodulations around the oxazolopyrimidine core (Figure 4) . The newly synthesized compounds were tested for their CB2 vs CB1 affinity in a binding assay, their efficacy toward CB2, and their metabolic stability in mice liver microsomes. 
In vitro binding assays and cytotoxicity
The affinities of each synthesized compound for CB receptors were determined by a competitive radioligand displacement assay using the dual CB1/CB2 ligand In summary, the structure-activity relationship (SAR) studies indicate that piperazine moieties at the C7 position favor CB2 binding affinities of the molecules.
Notably, lipophilic piperazine moieties (i.e., methylpiperazine and ethylpiperazine)
are preferred for CB2 affinity rather than a hydrophilic piperazine moiety (i.e., acetylpiperazine). However, there seems to be steric limitations due to a sudden The cytotoxicity of these compounds was determined at 10 μM using a cell proliferation assay on Chinese hamster ovary cells wild type (CHO-WT), Chinese hamster ovary cells expressing CB2 receptors (CHO-CB2), and human colorectal adenocarcinoma cells HT29. This test is based on a colorimetric method, which measures the activity of cellular enzymes that reduce the tetrazolium dye (MTS, yellow) to its insoluble formazan, giving a purple color. This assay measures cellular metabolic activity via NADPH-dependent cellular oxidoreductase enzymes and reflects, under defined conditions, the number of viable cells [5, 42] . No significant cytotoxicity over 72h was observed for these new compounds.
Cyclic adenosine monophosphate (cAMP) assays
Eight compounds displaying potent CB2 affinity were further studied for their functionality by cAMP assays in CHO-CB2 cells. Cells were treated with forskolin (3 μM) in order to activate adenylyl cyclase and thereby producing cAMP [43] [44] [45] . CB2
ligands can be classified as agonists, neutral antagonists, or inverse agonists regarding to their functional effects on cAMP formation. Agonists inhibit forskolin-induced cAMP production, whereas inverse agonists promote cAMP production. On the contrary, neutral antagonists do not significantly alter cAMP levels [46, 47] . As shown in Table 2 does not alter the binding affinity of the molecule toward CB2, it appears to alter the biological response from a CB2 agonist to competitive neutral antagonist. Data represent the mean ± SEM of at least three experiments performed in duplicate.
Metabolic stability in mice liver microsomes
These eight potent CB2 ligands have also been examined for their in vitro metabolic stability in the presence of mice liver microsomes ( Figure 7 , Table 3 progressed. To the best of our knowledge, research on neutral antagonists is rare.
Indeed, the first reported antagonist SR144528 was then identified to behave as an inverse agonist [16, 49] . Some purported "antagonists" are actually inverse agonists [50] [51] [52] [53] [54] . The real first reported CB2 neutral antagonist may be WIN55212-3 ( Figure 8 ),
an enantiomer of WIN55212-2, but it showed weak affinity toward CB2 (Ki > 1 μM).
Another reported CB2 neutral antagonist is XIE35-1001 ( Figure 8 ) [55] . However, data in a cAMP assay or [ Notably, compounds 47 and 48, which display nanomolar potency and behave as competitive neutral antagonists toward CB2, may serve as lead compounds for further studies. Furthermore, we will continue the structural optimization of these oxazolepyrimidines to improve their metabolic stability so that they can be suitable for systemic applications. A solution of benzoyl chloride or ortho halogenated benzoyl chloride (4.8 mmol,
equiv) and aminomalononitrile p-toluenesulfonate (4 mmol, 1 equiv) in 15 mL
NMP was stirred at room temperature for 10 min, and then heated by microwave irradiation at 80 °C for 25 min. At the end of the reaction, after cooling, the solution was diluted with 100 mL saturated brine and neutralized (pH ~8) to give a white precipitate, which was further recrystallized in CH2Cl2 to afford compounds 11-14.
These compounds were used for the next reaction.
Synthesis of 2-(2-chlorophenyl)oxazolo[5,4-d]pyrimidin-7-amine (15)
A solution of compound 13 (2.5 mmol, 1 equiv) and formamidine acetate (3 mmol, 1.2 equiv) in 15 mL NMP was stirred and heated at 100 °C for 3 h. At the end of the reaction, after cooling, the solution was diluted with 100 mL saturated brine to give a white precipitate, which was recrystallized in CH2Cl2 to afford compound 15.
This compound was used for the next reaction. 
N-Butyl-2-(2-chlorophenyl)oxazolo[5,4-d]pyrimidin-7-amine (17)
The 4.1.14.1.
The title compound was obtained as a yellow solid, mp 151-152 °C, purity incubation with microsomes denatured by acetonitrile containing the internal standard. Propranolol was used as a positive control. Analysis was determined by UPLC-MS/MS (Waters * Acquity I-Class / Xevo TQD) using a column (Waters
